Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOBILE_IC: Metformin in Intermittent Claudication
NCT05132439Phase 3Recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Mar 2022
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of liquid metformin (Aspargo Labs) in Peripheral Arterial Disease (PAD) and intermittent claudication (IC) (2 arms), sponsored by VA Office of Research & Development. Primary endpoint: Maximal Walking distance on the 6 minute walk test at 6 months. Started Mar 2022; status: recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
Peripheral Arterial Disease (PAD)intermittent claudication (IC)
Beyond the preview
Go deeper on NCT05132439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05132439.